Randomized Clinical Trials in Gastric Cancer

Surgical Oncology Clinics of North America

Volumn 19, Issue 1, 2010, Pages 81-100

  Mezhir, James J ^a   Pillarisetty, Venu G ^a   Shah, Manish A ^a   Coit, Daniel G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Chemotherapy; Gastric cancer; Neoadjuvant therapy; Randomized clinical trial; Surgery

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; AMOXICILLIN; ANTINEOPLASTIC AGENT; CAPECITABINE; CEFAZOLIN; CISPLATIN; CLARITHROMYCIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; LANSOPRAZOLE; MITOMYCIN C; OXALIPLATIN; SULTAMICILLIN;

ABDOMINAL ABSCESS; ABDOMINAL BLEEDING; ABDOMINAL DRAINAGE; ABDOMINAL PAIN; ANASTOMOSIS LEAKAGE; ANEMIA; ANOREXIA; ANTIBIOTIC PROPHYLAXIS; BILE REFLUX; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENDOSCOPIC MUCOSAL RESECTION; ERADICATION THERAPY; FEVER; GASTRECTOMY; GASTRECTOMY BILLROTH I; HELICOBACTER INFECTION; HUMAN; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; LEUKOPENIA; LUNG DISEASE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MINIMALLY INVASIVE SURGERY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NOSE FEEDING; PERIOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; REVIEW; ROUX Y ANASTOMOSIS; SINGLE DRUG DOSE; SPLENECTOMY; STOMACH CANCER; SUBPHRENIC ABSCESS; SURGICAL APPROACH; SURGICAL INFECTION; SURGICAL MORTALITY; TOTAL STOMACH RESECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 70449411496     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2009.09.011     Document Type: Review

References (46)

1. Weber S.M., and Karpeh M.S. Randomized clinical trials in gastric cancer. Surg Oncol Clin N Am 11 1 (2002) 111-131 ix
2. Bonenkamp J.J., Hermans J., Sasako M., et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 340 12 (1999) 908-914
3. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79 9-10 (1999) 1522-1530
4. Hartgrink H.H., van de Velde C.J., Putter H., et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22 11 (2004) 2069-2077
5. Wu C.W., Hsiung C.A., Lo S.S., et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 7 4 (2006) 309-315
6. Sasako M., Sano T., Yamamoto S., et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359 5 (2008) 453-462
7. Yonemura Y., Wu C.C., Fukushima N., et al. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 13 2 (2008) 132-137
8. Sasako M., Sano T., Yamamoto S., et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 7 8 (2006) 644-651
9. Csendes A., Burdiles P., Rojas J., et al. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 131 4 (2002) 401-407
10. Yu W., Choi G.S., and Chung H.Y. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 93 5 (2006) 559-563
11. Huscher C.G., Mingoli A., Sgarzini G., et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann Surg 241 2 (2005) 232-237
12. Kitano S., Shiraishi N., Fujii K., et al. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery 131 Suppl 1 (2002) S306-S311
13. Hayashi H., Ochiai T., Shimada H., et al. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surg Endosc 19 9 (2005) 1172-1176
14. Kim Y.W., Baik Y.H., Yun Y.H., et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 248 5 (2008) 721-727
15. Lee J.H., Han H.S., and Lee J.H. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. Surg Endosc 19 2 (2005) 168-173
16. Mohri Y., Tonouchi H., Kobayashi M., et al. Randomized clinical trial of single- versus multiple-dose antimicrobial prophylaxis in gastric cancer surgery. Br J Surg 94 6 (2007) 683-688
17. Ishikawa M., Kitayama J., Kaizaki S., et al. Prospective randomized trial comparing Billroth I and Roux-en-Y procedures after distal gastrectomy for gastric carcinoma. World J Surg 29 11 (2005) 1415-1420 [discussion: 1421]
18. Iivonen M.K., Koskinen M.O., Ikonen T.J., et al. Emptying of the jejunal pouch and Roux-en-Y limb after total gastrectomy-a randomised, prospective study. Eur J Surg 165 8 (1999) 742-747
19. Fein M., Fuchs K.H., Thalheimer A., et al. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial. Ann Surg 247 5 (2008) 759-765
20. Kim J., Lee J., Hyung W.J., et al. Gastric cancer surgery without drains: a prospective randomized trial. J Gastrointest Surg 8 6 (2004) 727-732
21. Alvarez Uslar R., Molina H., Torres O., et al. Total gastrectomy with or without abdominal drains. A prospective randomized trial. Rev Esp Enferm Dig 97 8 (2005) 562-569
22. Doglietto G.B., Papa V., Tortorelli A.P., et al. Nasojejunal tube placement after total gastrectomy: a multicenter prospective randomized trial. Arch Surg 139 12 (2004) 1309-1313 [discussion: 1313]
23. Yoo C.H., Son B.H., Han W.K., et al. Nasogastric decompression is not necessary in operations for gastric cancer: prospective randomised trial. Eur J Surg 168 7 (2002) 379-383
24. Lee J.H., Hyung W.J., and Noh S.H. Comparison of gastric cancer surgery with versus without nasogastric decompression. Yonsei Med J 43 4 (2002) 451-456
25. Yang Z., Zheng Q., and Wang Z. Meta-analysis of the need for nasogastric or nasojejunal decompression after gastrectomy for gastric cancer. Br J Surg 95 7 (2008) 809-816
26. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 1 (2006) 11-20
27. Wang X.L., Wu G.X., Zhang M.D., et al. A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncol Rep 7 2 (2000) 241-244
28. Hartgrink H.H., van de Velde C.J., Putter H., et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 30 6 (2004) 643-649
29. Stahl M., Walz M.K., Stuschke M., et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27 6 (2009) 851-856
30. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 10 (2001) 725-730
31. Coit D. Adjuvant therapy for gastric cancer. J Am Coll Surg 205 Suppl 4 (2007) S54-S58
32. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357 18 (2007) 1810-1820
33. Di Costanzo F., Gasperoni S., Manzione L., et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 100 6 (2008) 388-398
34. De Vita F., Giuliani F., Orditura M., et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol 18 8 (2007) 1354-1358
35. Cascinu S., Labianca R., Barone C., et al. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 99 8 (2007) 601-607
36. Yu W., Whang I., Chung H.Y., et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 25 8 (2001) 985-990
37. Fukase K., Kato M., Kikuchi S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372 9636 (2008) 392-397
38. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24 31 (2006) 4991-4997
39. Ajani J.A., Moiseyenko V.M., Tjulandin S., et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25 22 (2007) 3205-3209
40. Ajani J.A., Moiseyenko V.M., Tjulandin S., et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 25 22 (2007) 3210-3216
41. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358 1 (2008) 36-46
42. Ross P., Nicolson M., Cunningham D., et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20 8 (2002) 1996-2004
43. Koizumi W., Narahara H., Hara T., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9 3 (2008) 215-221
44. Cocconi G., Carlini P., Gamboni A., et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 14 8 (2003) 1258-1263
45. Al-Batran S.E., Hartmann J.T., Probst S., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26 9 (2008) 1435-1442
46. Dank M., Zaluski J., Barone C., et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19 8 (2008) 1450-1457